ALLR

0.78509.25%
JR

Jeremy R. Graff

Interim Independent Chair

Dr. Jeremy R. Graff, Ph.D., serves as Director at IN8bio, Inc. since May 2023 and is its Interim Independent Chair from February 28, 2026. Dr. Graff serves as President and Chief Development Officer of Allarity Therapeutics, Inc. since October 2024. He served as Chief Scientific Officer at IMV Inc. since June 14, 2021 until January 2024. Form November 2023 to September 2024, Dr. Graff served as a consultant to the Company providing consulting and advisory services on its research and development programs in the field of small molecule inhibitors and their use in the treatment of cancer. Since January of 2024, Dr. Graff has also served as a C-Suite Executive Advisor and Consultant to a number of companies. Dr. Graff was Director of Allarity Therapeutics, Inc. from December 2023. Dr. Graff also serves as a member of the Board of Trustees for the Wood Hudson Cancer Research Laboratory and is on the Scientific Advisory Board of Avicenna Biosciences, Inc. He had been President at Biothera, Inc since December 2018 until June 2020 and had been its Chief Scientific Officer since 2014 until November 2018 and served as Senior Vice President of Research November 25, 2016 until November 2018. He served as Chief Development Officer and Senior Vice President, Research at HiberCell from June 2020 to March 2021. Dr. Graff served as the Senior Vice President of Research for Pharmaceutical Group at Biothera, Inc from November 2014 to November 25, 2016. Dr. Graff has extensive experience across the spectrum of drug discovery and development, having led numerous programs from target inception and screen enablement through early and late stage clinical development. His lab was the first to bring forward a therapy targeting the mRNA translational regulator, eIF4E. He also led the efforts to establish the therapeutic mechanism of action for numerous early phase clinical assets --most notably the small molecule kinase inhibitor, enzastaurin, in Diffuse Large B Cell Lymphoma and glioblastoma. Most recently, he shared responsibility for developing and leading the Translational Oncology efforts within Lilly Oncology. In addition to numerous project leadership roles, Dr. Graff was also intimately involved in establishing and leading many external Partnerships to enable human tissue-based translational research and to accelerate innovative tissue imaging techniques with General Electric. Dr. Graff is widely recognized as a prolific researcher, having published nearly 60 research articles that have garnered more than 14,000 research citations. From February 1998 to November 2014, he spent certain years at Eli Lilly and Lilly Research Labs where he developed extensive experience in cancer drug discovery and development, immuno-oncology, biomarker discovery and patient stratification. At Lilly Research Labs, he was the recipient of President’s Recognition Award, the Company’s highest annual award. He currently serves as a Senior Reviews Editor and Associate Editor for Cancer Research. He is also a grant review panelist for the American Cancer Society, the National Institutes of Health, the Department of Defense and Genome Quebec. He received a Ph.D. from the University of Kentucky’s Markey Cancer Center and completed a post-doctoral fellowship at the John Hopkins University Oncology Center. He has authored 60 peer-reviewed publications and holds a number of patents for novel cancer therapies. He completed a post-doctoral fellowship at the Johns Hopkins University School of Medicine. He holds a Bachelor of Arts degree in Biology and Chemistry from Thomas More College (now University).

Positions